|
|
|
|
Alternate Methods -- Subchronic and Chronic Toxicity
(Other than Carcinogenicity) |
|
Chronic [RfC]: (see comment) |
4E-2 mg/cu m |
|
Uncertainty Factor: |
1000 |
|
Subchronic [RfC]: (see comment) |
4E-2 mg/cu m |
|
Uncertainty Factor: |
1000 |
|
Route: |
Inhalation: intermittent |
|
Target Organ / Critical Effect: |
Nasal cavity / Lesions |
|
Species |
Effect Level |
Dose |
Experiment Length |
Mouse |
LOAEL |
11.2 mg/kg/day |
103 weeks |
|
References |
| Final chronic report performed for the NTP under Contract No. N01-ES-38042. |
1987 | U.S. EPA. 1987. Health and environmental effects document for Methyl styrenes. Prepared by the Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office, Cincinnati, OH for the Office of Solid Waste and Emergency Response, Washington, DC. |
|
Subchronic [RfC] Comments: |
1E-2 mg/kg/day (see Appendix A-II, Dose Conversions on HEAST). |
Chronic [RfC] Comments: |
1E-2 mg/kg/day (see Appendix A-II, Dose Conversions on HEAST). |
General Comments: |
The subchronic and chronic inhalation [RfC] values were derived from methodology that is not current with the interim inhalation methodology used by the RfD/RfC work group. |
|
|
|
|
Chronic [RfD]: (see comment) |
6E-3 mg/kg/day |
|
Uncertainty Factor: |
1000 |
|
Subchronic [RfD]: (see comment) |
6E-3 mg/kg/day |
|
Uncertainty Factor: |
1000 |
|
Route: |
Inhalation: intermittent |
|
Target Organ / Critical Effect: |
Nasal cavity / Lesions |
|
Species |
Effect Level |
Dose |
Experiment Length |
Mouse |
LOAEL |
5.6 mg/kg/day |
103 weeks |
|
References |
1984 | MRI (Midwest Research Institute). 1984. Study of the inhalation carcinogenicity (bioassay) of Vinyl Toluene in B6C3F1 mice. |
1987 | U.S. EPA. 1987. Health and environmental effects document for Methyl Styrenes. Prepared by the Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office, Cincinnati, OH for the Office of Solid Waste and Emergency Response, Washington, DC. |
|
Subchronic [RfD] Comments: |
Based on route to route extrapolation with an absorption factor of 0.5. |
Chronic [RfD] Comments: |
Based on route to route extrapolation with an absorption factor of 0.5. |
General Comments: |
No pharmacokinetic data were provided to justify route to route extrapolation for the oral [RfD] values. |
|